The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 16: 2062 - 2070

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.16.009

Clinical Research

Expression and prognosis of STT3A and STT3B in epithelial ovarian cancer

  • Chongfeng SUN ,
  • Ping YANG ,
  • Jishuai HOU ,
  • Zouyu ZHAO ,
  • Panpan. YU
Expand
  • *.Department of Gynecology，the First Affiliated Hospital，Shihezi University，Shihezi 832008，China
    *.Key Laboratory of Prevention and Treatment of Subhigh Incidence Diseases，National Health Commission of China，Shihezi 832008，China

Received date: 2023-02-14

  Online published: 2023-09-26

Fold

Abstract

Objective To explore the relationship between the expression levels of STT3A and STT3B in Epithelial Ovarian Cancer （EOC） and the clinicopathological features and prognosis of the patients. Methods The clinical information of 88 patients with EOC who underwent surgical treatment and 22 patients with normal tubal epithelium and normal ovarian tissue in our department from 2010 to 2019 were collected and followed up. The expressions of STT3A and STT3B in EOC and control groups were detected by immunohistochemistry， and their relationships with clinicopathological features and prognosis of patients were analyzed. Results The expression of STT3A and STT3B in EOC patients was significantly higher than that of control group （P < 0.05）， and the expression of STT3A was related to tumor differentiation degree and lymph node metastasis （P < 0.05）. The expression of STT3B was significantly correlated with FIGO staging， serum CA125 level， Lymph?vascular space invasion， degree of tumor differentiation and lymph node metastasis （P < 0.05）. Kaplan?Meier survival analysis showed that the higher expressions of STT3A and STT3B were associated with poor prognosis （P < 0.05）. Multivariate Cox regression analysis revealed that the high expressions of STT3A and STT3B were independent risk factors for the prognosis of EOC patients （P < 0.05）. Western Blot results showed that STT3A and STT3B were significantly expressed in ovarian cancer （P < 0.05）. Conclusion STT3A and STT3B are extremely expressed in EOC tissues and are associated with poor prognosis of EOC patients， and may be potential markers for the prognosis of EOC patients.

Key words： epithelial ovarian cancer; STT3A; STT3B; clinicopathological features; prognosis

Cite this article

Chongfeng SUN , Ping YANG , Jishuai HOU , Zouyu ZHAO , Panpan. YU . Expression and prognosis of STT3A and STT3B in epithelial ovarian cancer[J]. The Journal of Practical Medicine, 2023 , 39(16) : 2062 -2070 . DOI: 10.3969/j.issn.1006-5725.2023.16.009

References

1 SHI J， ZHANG L， ZHOU D，et al. Biological Function of Ribosomal Protein L10 on Cell Behavior in Human Epithelial Ovarian Cancer［J］. J Cancer，2018，9（4）：745-756.
2 戴燕，金世光，王薛洁，等.RNA结合蛋白Larp1在卵巢癌侵袭转移中的作用及机制［J］.实用医学杂志，2018，34（1）：21-25.
3 THOMAS D， RATHINAVEL A K， RADHAKRISHNAN P. Altered glycosylation in cancer： A promising target for biomarkers and therapeutics［J］. Biochim Biophys Acta Rev Cancer， 2021， 1875（1）：188464.
4 路佩佩，刘风玲.肿瘤糖基化在肿瘤免疫逃避中的意义［J］.肿瘤学杂志，2020，26（5）：371-375.
5 SHU J， DANG L， ZHANG D， et al. Dynamic analysis of proteomic alterations in response to N-linked glycosylation inhibition in a drug-resistant ovarian carcinoma cell line［J］. FEBS J， 2019， 286（8）：1594-1605.
6 金夏雨，王宜生，徐丛剑，等.蛋白质异常糖基化与卵巢上皮性癌发生发展关系的研究进展［J］.中华妇产科杂志，2022，57（5）：397-400.
7 PRADOS M B， SICA M P， MIRANDA S. Inflammatory conditions promote a switch of oligosaccharyltransferase （OST） catalytic subunit isoform expression［J］. Arch Biochem Biophys，2020，693：108538.
8 BRAUNGER K， PFEFFER S， SHRIMAL S， et al. Structural basis for coupling protein transport and N-glycosylation at the mammalian endoplasmic reticulum［J］. Science， 2018， 360（6385）：215-219.
9 SHIH I M， WANG Y， WANG T L. The Origin of Ovarian Cancer Species and Precancerous Landscape［J］. Am J Pathol， 2021， 191（1）：26-39.
10 ZHONG F， LIU S， HU D，et al. LncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosis［J］. J Cancer，2022，13（3）：1048-1060.
11 冯同富，陈德军，叶常鸿，等.视黄醇结合蛋白2基因沉默对卵巢癌SKOV3/PTX细胞迁移侵袭的影响［J］.实用医学杂志，2021，37（10）：1240-1244.
12 PATEL M R， STADLER M E， DEAL A M， et al. STT3A， C1orf24， TFF3： putative markers for characterization of follicular thyroid neoplasms from fine-needle aspirates［J］. Laryngoscope， 2011， 121（5）：983-989.
13 CHENG J， XIA L， HAO X， et al. Targeting STT3A produces an anti-tumor effect in lung adenocarcinoma by blocking the MAPK and PI3K/AKT signaling pathway［J］. Transl Lung Cancer Res， 2022， 11（6）：1089-1107.
14 DING J， XU J， DENG Q， et al. Knockdown of Oligosaccharyltransferase Subunit Ribophorin 1 Induces Endoplasmic-Reticulum-Stress-Dependent Cell Apoptosis in Breast Cancer［J］. Front Oncol， 2021， 11：722624.
15 RUAN Z， LIANG M， LAI M， et al. KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the beta-catenin/STT3 signaling pathway［J］. Int Immunopharmacol， 2020， 78：106003.
16 MA X M， LUO Y F， ZENG F F， et al. TGF-beta1-Mediated PD-L1 Glycosylation Contributes to Immune Escape via c-Jun/STT3A Pathway in Nasopharyngeal Carcinoma［J］. Front Oncol， 2022， 12：815437.
Options
Outlines

/

〈 〉